Omrix outlines plan for $55M offering

Omrix Biopharmaceuticals plans to raise $55 million in an IPO priced at $15 to $17 a share. The offering sets a midpoint valuation of the company at $229 million. The company plans to trade on NASDAQ as OMRI. If the IPO proceeds as planned, Omrix CEO Robert Taub will see his stake in the company drop from 32.1 percent to 24.4 percent.

- read the report from Globes

Suggested Articles

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.

The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.”

Trutino will apply a platform designed to yield safer, more effective cytokines to the discovery of three oncology drugs for Boehringer.